SCHEDULE 13G: Woodline Partners Discloses 7.5% Stake in Outset Medical, Inc.

Woodline Partners LP, an investment adviser, has disclosed a passive beneficial ownership of 7.5% of Outset Medical, Inc.'s common stock.

Summary

• Woodline Partners LP, a Delaware limited partnership and investment adviser to Woodline Master Fund LP, has filed a Schedule 13G.
• The filing indicates beneficial ownership of 1,325,784 shares of Outset Medical, Inc. common stock.
• This stake represents 7.5% of the company's outstanding common stock.
• The percentage is calculated based on approximately 17,699,595 shares of Common Stock outstanding, which accounts for a 1-for-15 reverse stock split effected on March 20, 2025.
• Woodline Partners LP holds both shared voting power and shared dispositive power over these shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The disclosure of a significant passive stake by an institutional investor is generally viewed as a neutral to mildly positive signal, indicating institutional confidence without implying activist intentions or immediate operational changes.

Positives

• The disclosure of a 7.5% stake by Woodline Partners LP, a sophisticated institutional investor, may signal confidence in Outset Medical, Inc.'s long-term prospects.
• The investment is certified as passive, indicating a long-term holding strategy rather than an activist intent.

Future Outlook

The document does not provide any forward-looking statements or guidance regarding Outset Medical, Inc.'s future performance or strategic direction.

Industry Context

This filing indicates an institutional investor's significant stake in a medical device company, reflecting ongoing investment activity within the healthcare technology sector. While the filing itself doesn't provide industry trends, it highlights continued investor interest in companies like Outset Medical, Inc. operating in the medical technology space.

Stakeholder Impact

• Shareholders: The disclosure of a new significant institutional investor may positively influence market perception and potentially attract further institutional interest, potentially impacting share price.

Key Dates

Keywords

Outset Medical, Woodline Partners, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Medical Devices, Healthcare, SEC Filing